DOCSLIB.ORG

CVS CAREMARK CORP Mailing Address Business Address ONE CVS DR

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CVS CAREMARK CORP Mailing Address Business Address ONE CVS DR SECURITIES AND EXCHANGE COMMISSION FORM 10-K Annual report pursuant to section 13 and 15(d) Filing Date: 2010-02-26 | Period of Report: 2009-12-31 SEC Accession No. 0001193125-10-043086 (HTML Version on secdatabase.com) FILER CVS CAREMARK CORP Mailing Address Business Address ONE CVS DR. ONE CVS DR. CIK:64803| IRS No.: 050494040 | State of Incorp.:DE | Fiscal Year End: 1231 WOONSOCKET RI 02895 WOONSOCKET RI 02895 Type: 10-K | Act: 34 | File No.: 001-01011 | Film No.: 10640360 4017651500 SIC: 5912 Drug stores and proprietary stores Copyright © 2012 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2009 OR ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-01011 CVS CAREMARK CORPORATION (Exact name of Registrant as specified in its charter) Delaware 050494040 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) One CVS Drive Woonsocket, Rhode Island 02895 (Address of principal executive offices) (Zip Code) (401) 765-1500 (Registrants telephone number, including area code) Securities registered pursuant to Section 12(b) of the Exchange Act: Common Stock, par value $0.01 per share New York Stock Exchange Title of each class Name of each exchange on which registered Securities registered pursuant to Section 12(g) of the Exchange Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes x No ¨ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨ No x Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨ Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨ Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrants knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ¨ Copyright © 2012 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, or a smaller reporting company. See definition of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. Large accelerated filer x Accelerated filer ¨ Non-accelerated filer ¨ (Do not check if a smaller reporting company) Smaller reporting company ¨ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ¨ No x The aggregate market value of the registrants common stock held by non-affiliates was approximately $46,267,935,658 as of June 30, 2009, based on the closing price of the common stock on the New York Stock Exchange. For purposes of this calculation, only executive officers and directors are deemed to be the affiliates of the registrant. As of February 22, 2010, the registrant had 1,390,515,000 shares of common stock issued and outstanding. DOCUMENTS INCORPORATED BY REFERENCE Filings made by companies with the Securities and Exchange Commission sometimes incorporate information by reference. This means that the company is referring you to information that was previously filed or is to be filed with the SEC, and this information is considered to be part of the filing you are reading. The following materials are incorporated by reference into this Form 10-K: Information contained on pages 22 through 71, and page 73 of our Annual Report to Stockholders for the fiscal year ended December 31, 2009 is incorporated by reference in our response to Items 7, 8 and 9 of Part II. Information contained in our Proxy Statement for the 2010 Annual Meeting of Stockholders is incorporated by reference in our response to Items 10 through 14 of Part III. Copyright © 2012 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Table of Contents TABLE OF CONTENTS Page Part I Item 1: Business 3 Item 1A: Risk Factors 22 Item 1B: Unresolved Staff Comments 27 Item 2: Properties 27 Item 3: Legal Proceedings 29 Item 4: Submission of Matters to a Vote of Security Holders 31 Executive Officers of the Registrant 32 Part II Item 5: Market for Registrants Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 34 Item 6: Selected Financial Data 35 Item 7: Managements Discussion and Analysis of Financial Condition and Results of Operations 36 Item 7A: Quantitative and Qualitative Disclosures About Market Risk 36 Item 8: Financial Statements and Supplementary Data 36 Item 9: Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 36 Copyright © 2012 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Item 9A: Controls and Procedures 36 Item 9B: Other Information 37 Part III Item 10: Directors and Executive Officers of the Registrant 38 Item 11: Executive Compensation 38 Item 12: Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 38 Item 13: Certain Relationships and Related Transactions and Director Independence 38 Item 14: Principal Accountant Fees and Services 38 Part IV Item 15: Exhibits, Financial Statement Schedules 39 Report of Independent Registered Public Accounting Firm Schedule II Valuation and Qualifying Accounts 45 Signatures 46 2 Copyright © 2012 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Table of Contents PART I Item 1. Business Overview CVS Caremark Corporation (CVS Caremark, the Company, we or us) is the largest pharmacy health care provider in the United States. As a fully integrated pharmacy services company, we believe we can drive value for our customers by effectively managing pharmaceutical costs and improving health care outcomes through our pharmacy benefit management, mail order and specialty pharmacy division, Caremark Pharmacy Services®; approximately 7,000 CVS/pharmacy® retail stores; our retail-based health clinic subsidiary, MinuteClinic®; and our online pharmacy, CVS.com®. In March 2007, we completed our merger with Caremark Rx, Inc. (the Caremark Merger). Following the Caremark Merger, we changed our name to CVS Caremark Corporation and Caremark Rx, Inc. became a wholly-owned subsidiary, Caremark Rx, L.L.C. (Caremark). The Caremark Merger brought together the nations largest retail pharmacy chain and a leading pharmacy benefit manager. We believe the Caremark Merger has uniquely positioned our Company to deliver significant benefits to health plan sponsors through effective cost management solutions and innovative programs that engage plan members and promote healthier and more cost-effective behaviors. In addition, the Caremark Merger has enhanced our ability to offer plan members and consumers expanded choice, greater access and more personalized services. Business Segments During the third quarter of 2009, we made changes to our reportable segments to reflect changes that were made to the way our management evaluates the performance of operations, develops strategy and allocates resources. This change involves recording certain administrative expenses previously recorded within the Pharmacy Services and Retail Pharmacy segments in a new Corporate segment. The Corporate segment consists of costs primarily associated with executive management, corporate relations, legal, compliance, human resources, corporate information technology and finance. This change had no impact on our consolidated results of operations. As a result of this change, the Company has three segments: Pharmacy Services, Retail Pharmacy and Corporate. Our historical segment disclosures have been revised to conform to the current presentation. During the third quarter of 2009, we also made a change to our Pharmacy Services segment as it relates to our intersegment activities (such as the Maintenance Choice® program). This change impacts the gross profit and operating profit lines within the Pharmacy Services segment. Under the Maintenance Choice program, eligible members in plans sponsored by Pharmacy Services clients can elect to pick up their maintenance prescriptions at Retail Pharmacy segment stores instead of receiving them through the mail. When this occurs, both the Pharmacy Services and Retail Pharmacy segments now record the revenue, gross profit and operating profit on a standalone basis and corresponding
Load more

Recommended publications
  • TC-017 Butterfield, Dawn (National Community Pharmacy Association)
    Peter Mucchetti, Chief Healthcare and Consumer Products Section, Antitrust Division Department of Justice 450 Fifth Street NW, Suite 4100 Washington, DC 20530 December 13, 2018 Dear Judge Leon: Thank you so much for inviting or allowing comments on the proposed CVS/Aetna merger. We (pharmacy owners/pharmacists) were not happy when our own organization - NCPA - National Community Pharmacy Association was referenced in the Congressional Hearing on this merger earlier in the year that "we were fine" with the merger as expressed by Tom Moriarty - CVS General Counsel to the Congressional Committee. This most assuredly is NOT the case I can assure you. However that was communicated - and not clarified by our association is an issue we are all still highly upset about as I believe that was the time to publicly state our vehement opposition to this merger. In other words, a major ball was dropped and a bell was rung that couldn't be unrung. That being said - we, as business owners and professionals don't know how we can state our issues - which are numerous and we were being told by virtually everyone that the merger is a "done deal" as the FTC and DOJ didn't have an issue with it. I hope you receive communication from people who took the time to do so. Some people are frozen and/or feel defeated as they believe there's nothing to stop this train and have given up. I can say with certainty that for every letter from a pharmacist/pharmacy owner/pharmacy professor - there were 1000 that went along with it! I'm enclosing some material you may already have, but the infographic on the states shows to the extent of what can happen when your competition sets YOUR price.
    [Show full text]
  • CVS Pharmacy Network
    Participating Retail Pharmacies The following list shows the major chain pharmacies and affiliated groups of independent community pharmacies that accept your prescription benefit ID card. In addition to these, most independent pharmacies nationwide also take part in your prescription program. To find out if a pharmacy not listed here accepts your card, call the pharmacy directly. A C (continued) G (continued) A & P Pharmacy CVS Caremark Specialty Pharmacy Giant Eagle Pharmacy AAP / United Drugs CVS/Longs Giant Pharmacy Accredo Health Group, Inc. CVS/pharmacy Good Neighbor Pharmacy ACME Pharmacy Albertson’s Pharmacy American Pharmacy Cooperative / D H American Pharmacy Network Solutions Dahl’s Pharmacy Haggen Pharmacy American Home Patient Dierbergs Pharmacy Hannaford Food & Drug American Pharmacy Dillon Pharmacy Happy Harry’s Ameridrug Pharmacy Discount Drug Mart Harmons Pharmacy Apria Healthcare, Inc. Doc’s Drugs Harps Pharmacy Doctor’s Choice Pharmacy Aurora Pharmacy Harris Teeter Pharmacy Dominick’s Pharmacy Harvard Drug Drug Town Pharmacy Harvard Vanguard Medical Association B Drug Warehouse Harveys Supermarket Pharmacy Baker’s Pharmacy Drug World H-E-B Pharmacy Bartell Drugs Drugs for Less Health Mart Basha’s United Drug Duane Reade HealthPartners Bel Air Pharmacy Duluth Clinic Hen House Pharmacy Bi-Lo Pharmacy Henry Ford Pharmacy Bi-Mart Pharmacy Hi-School Pharmacies Biggs Pharmacy E Hilander Pharmacy Bioscrip Pharmacy EPIC Homeland Pharmacy Bloom Pharmacy Eaton Apothecary Horton & Converse Brookshire Brothers Pharmacy Econofoods
    [Show full text]
  • Joint Proxy Statement of CVS Corporation and Caremark Rx, Inc
    MERGER PROPOSED YOUR VOTE IS VERY IMPORTANT The boards of directors of CVS Corporation and Caremark Rx, Inc. have each approved a merger agreement which provides for the combination of the two companies in a transaction structured as a merger of equals. The boards of directors of CVS and Caremark believe that the combination of the two companies will be able to create substantially more long-term stockholder value than either company could individually achieve. Following the completion of the merger, Caremark will be a wholly owned subsidiary of CVS and Caremark stockholders will own approximately 45.5% of the outstanding common stock of the combined company and CVS stockholders will own approximately 54.5% of the outstanding common stock of the combined company, in each case, on a fully diluted basis. CVS Corporation is referred to as CVS and Caremark Rx, Inc. is referred to as Caremark. The combined company will be named CVS/Caremark Corporation and the shares of the combined company will be traded on the New York Stock Exchange, or the NYSE, under the symbol CVS . If the merger is completed, Caremark s stockholders will receive 1.670 shares of common stock of CVS/Caremark, for each share of Caremark common stock that they own immediately before the effective time of the merger. Caremark stockholders will receive cash for any fractional shares which they would otherwise receive in the merger. Caremark stockholders will also receive a one-time special cash dividend in the amount of $2.00 per share of Caremark common stock held by each such holder on a record date to be set by the Caremark board of directors, which dividend will be conditioned on the completion of the merger and will be paid at or immediately following the effective time of the merger.
    [Show full text]
  • CVS Digital Capabilities
    Digital Capabilities Connecting members, patients and customers to our services anytime, anywhere. Table of Contents Our Digital Strategy ............... 4 Helping people save CVS Caremark® ...................... 6 time, save money CVS Specialty® ....................... 8 Omnicare® and and stay healthy. Medicare Part D ................... 10 CVS Pharmacy® and Here at CVS Health, we’re reinventing pharmacy to help people on their CVS MinuteClinic™ ............... 12 path to better health. Our commitment to digital innovation is one way we’re putting our purpose into action. Front Store ............................ 14 Throughout all of our service brands, we offer members, patients and customers a suite of digital tools that make managing their health more accessible, more intuitive and more integrated across all our channels. Moving forward, we’ll continue to transform the future of health care by redefi ning convenience and improving the health outcomes of millions of people. 2 3 Build Develop the ultra-convenient, fully integrated pharmacy Our experience only CVS Health can provide across our service brands (CVS Pharmacy, Digital CVS MinuteClinic, CVS Caremark, Strategy CVS Specialty and Omnicare). Digital tools are Personalize transforming the way Provide individualized customer consumers shop and interactions, leveraging data across manage their health care. all touch points to help members, patients and customers on their We’re responding to path to better health. these changing needs by differentiating the customer experience through three Innovate strategic pillars. Harness critical digital trends through rapid testing/learning/ iteration and third-party collaboration at the CVS Health Digital Innovation Lab. 4 5 Member Set Up Print Rx History Easy Refill Makes budgeting and tax prep Offers members a simple way Early Registration easier by allowing members to to refill by scanning the barcode Allows members to register and print a list of prescription costs.
    [Show full text]
  • The Power Of
    A DSN SPECIAL REPORT n 2012, DSN presented an in-depth report on CVS Caremark’s integrated pharmacy business model — part big retail pharmacy chain, part big PBM, part big retail clinic operator — and the innova- tive products and solutions that were coming out of the organization, particularly where the three parts of Ithe business came together, its “integration sweet spots,” as company executives referred to them. It was clear at the time that the company had emerged as a “category of one,” which was the cover theme of that special issue. Now, a year later, as the company completes its 50th year in business and the country awaits a period of change in health care unlike anything seen in at least that time, CVS Caremark executives are quite confident that its unique hybrid structure and its ability to leverage the three core parts of its business — either individually or together, in varying combinations to serve a multitude of needs — aligns more effectively with the long-term trends in health care and puts the company in a unique position at a singular moment in history. In an exclusive interview with DSN, CVS Caremark president and CEO Larry Merlo talked about what that means, why it’s important to both public and private pay- ers of all sizes, health plans, patients and providers, as well as how the company is using behavioral economics and predictive analytics to more effectively engage clients and customers and how they are building new clinical capabilities to address the new models of care, new cus- tomers and new quality standards that will guide the new payment models that will emerge through health reform.
    [Show full text]
  • Driving More Affordable, Accessible and Effective Care
    Driving More Affordable, Accessible and Effective Care Larry Merlo President & Chief Executive Officer Forward-looking Statements; Non-GAAP Measures During today’s presentation, we will make forward-looking statements within the meaning of the federal securities laws. By their nature, all forward-looking statements involve risks and uncertainties. Actual results may differ materially from those contemplated by the forward-looking statements for a number of reasons as described in our SEC filings, including the risk factors section and cautionary statement disclosure in those filings. During this presentation, we will also use some non-GAAP financial measures when talking about our company’s performance, including free cash flow, cash available to enhance shareholder value and Adjusted EPS. In accordance with SEC regulations, you can find the definitions of these non-GAAP items, as well as reconciliations to comparable GAAP measures, on the investor relations portion of our website. 2 Key Accomplishments in 2016 Strong financial performance Enhanced Long-Term Care Adjusted EPS growth of ~12%; Introduced pilot programs to improve Free Cash Flow of $6.9B patient care Successful PBM selling season Completed Target integration $7.8B gross new business for 2017; Integrated Target pharmacies and clinics client retention of ~97% Effectively managed trend Advanced front store strategies Delivered profitable sales through Achieved client drug trend of only 3.3% enhanced offerings, personalization through September and digital capabilities Superior Specialty growth Plan to reaccelerate growth Includes new partnerships with payors, Dispensed revenue growth of ~19%, new PBM products, cost savings initiative continuing to outpace market and capital deployment 3 Refer to endnotes for additional information.
    [Show full text]
  • Participating Retail Pharmacies
    Participating Retail Pharmacies The following list shows the major chain pharmacies and affiliated groups of independent community pharmacies that accept your prescription benefit ID card. In addition to these, most independent pharmacies nationwide also take part in your prescription program. To find out if a pharmacy not listed here accepts your card, call the pharmacy directly. A D H A & P Pharmacy Dahl’s Pharmacy Haggen Pharmacy AAP / United Drugs Dierbergs Pharmacy Hannaford Food & Drug Accredo Health Group, Inc. Dillon Pharmacy Happy Harry’s ACME Pharmacy Discount Drug Mart Harmons Pharmacy Albertson’s Pharmacy Doc’s Drugs Harps Pharmacy American Pharmacy Cooperative / Doctor’s Choice Pharmacy Harris Teeter Pharmacy American Pharmacy Network Solutions Dominick’s Pharmacy Harvard Drug American Home Patient Drug Town Pharmacy Harvard Vanguard Medical Association American Pharmacy Drug Warehouse Harveys Supermarket Pharmacy Apria Healthcare, Inc. Drug World H-E-B Pharmacy Aurora Pharmacy Drugs for Less Health Mart Duane Reade HealthPartners Duluth Clinic Hen House Pharmacy B Henry Ford Pharmacy Baker’s Pharmacy Hi-School Pharmacies Bartell Drugs E Homeland Pharmacy Basha’s United Drug EPIC Horton & Converse Bel Air Pharmacy Eaton Apothecary Hy-Vee Pharmacy Bi-Lo Pharmacy Econofoods Bi-Mart Pharmacy Biggs Pharmacy I Bioscrip Pharmacy F IHC Health Center Bloom Pharmacy Fagen Pharmacy Infusion Partners Brookshire Brothers Pharmacy Fairview Ingles Pharmacy Brookshire Pharmacy Family Care Bruno’s Food and Pharmacy Family Pharmacy Farm Fresh
    [Show full text]
  • CVS 2755 Hollywood Ave Shreveport LA
    CVS OFFERING MEMORANDUM 2755 Hollywood Avenue| Shreveport, LA ™ Representative Photo CVS, Shreveport, LA | 1 ™ Representative2 | Offering Photo Memorandum contents 04 investment highlights 05 financial OVERVIEW 06 tenant overview 10 area OVERVIEW exclusively listed by rahul chhajed Senior Associate [email protected] DIR (949) 432-4513 MOB (818) 434-1106 LIC # 01986299 (CA) michael moreno Senior Associate [email protected] DIR (949) 432-4511 MOB (818) 632-1497 LIC # 01982943 (CA) aron cline SVP & Senior Director [email protected] DIR (949) 432-4509 MOB (818) 632-0233 LIC # 01904371 (CA) Beau j. box BROKER OF RECORD LIC # BROK.0000072286.A-ACT CVS, Shreveport,Representative LA | 3Photo executive summary Representative Photo investment highlights • 10,908 SF Freestanding CVS (BBB+ S&P) on Approximately 1.57 Acres • Primary Lease Term Through 12/31/18 with Four Renewal Options Remaining • Hard Corner at Signalized Intersection • Excellent Signage and Visibility • ± 140,000 residents within a 5-mile radius • Building is situated on a ± 1.57 AC lot 4 | Offering Memorandum financial overview CVS Annualized Operating Data 2755 Hollywood Avenue Monthly Rent Annual Rent Cap Rate Increases Shreveport, LA 71108 Current - 12/31/2018 $25,320.93 $303,851.10 20.26% 1.70% List Price .................................................................................. $1,500,000 Option 1 $25,775.43 $309,305.10 20.60% 1.70% Option 2 $26,229.93 $314,759.10 20.95% 1.70% CAP Rate - Current ....................................................................... 20.26% Option 3 $26,684.43 $320,213.10 21.31% 1.70% Gross Leasable Area ............................................................± 10,908 SF Option 4 $27,138.93 $325,667.10 21.67% 1.70% Lot Size .................................................................................
    [Show full text]
  • Statement for the Record: the National Community Pharmacists Association (NCPA)
    Statement for the Record: The National Community Pharmacists Association (NCPA) United States House Subcommittee on Regulatory Reform, Commercial and Antitrust Law Hearing: “Competition in the Pharmaceutical Supply Chain: The Proposed Merger of CVS Health and Aetna” February 27, 2018 Chairman Marino and Ranking Member Cicilline, and Members of the Subcommittee: Thank you for conducting this hearing on competition in the pharmaceutical supply chain and on the pending merger of CVS Health and Aetna Inc. that is currently under review at the Antitrust Division of the Department of Justice (“DOJ”). NCPA represents America’s community pharmacists, including the owners of more than 22,000 independent community pharmacies. Together they represent an $80 billion healthcare marketplace and employ more than 250,000 individuals on a full or part-time basis. These pharmacies dispense approximately 40% of all community pharmacy prescriptions and are often located in underserved rural or urban areas. In this statement, NCPA will highlight how increased consolidation in the healthcare industry may be contributing to higher costs and negatively impacting patient choice. NCPA will also address several potential issues and pose questions related to the CVS Health/Aetna Inc. merger and the broader implications on the healthcare industry. NCPA recommends that the proposed merger between CVS Health and Aetna Inc. be closely examined to determine whether this transaction will lead to lower quality/fewer options for patients, higher costs, and less competition in the healthcare market. Potential Implications on Pharmacy Choice for Patients The proposed CVS Health/Aetna Inc. merger raises several questions regarding its impact on pharmacy choice for patients.
    [Show full text]
  • Walgreens: Strategic Evolution1
    Walgreens: Strategic Evolution1 America’s largest drugstore chain, Walgreens, had 8,210 locations by 2011, including 7,761 drugstores. Almost 75 percent of Americans lived within five miles of a Walgreens pharmacy, and more than 6 million customers were served each day. Walgreens issued more than 800 million prescriptions annually, representing 20 percent of the U.S. market. Its online business, Walgreens.com, had almost 17 million visitors per month. Walgreens’ strategy had evolved for more than a century in business. By 2012, the company faced a number of major strategic questions, including international expansion and a changing health care environment. History of Pharmacy2 People have been trying to create remedies for illnesses and ailments since the beginning of time, but most historians credit Babylon with the first organized apothecary. This was followed by the Romans, who created a system of pathology and therapy that became standards for Western medicine for more than 1,000 years. For the most part, though, pharmacy remained a sketchy and shadowy business for centuries, practiced by (among others) witch doctors and alchemists. Advances in medicine and the Renaissance era led to more structured and scientific approaches. In 1240, German Emperor Frederick II issued a proclamation establishing the practice of pharmacy along three tenets: (1) separation of the pharmaceutical profession from the medical profession; (2) official supervision (regulation) of pharmacy; and (3) “obligation to prepare drugs reliably, according to skilled art, and in a uniform, suitable quality.”3 Public pharmacies and university training began spreading throughout Europe. 1 This case was written by John S.
    [Show full text]
  • NCPDP NPI Name 0353780 1962446211 CVS PHARMACY 0400363 1235114208
    NCPDP NPI Name 0353780 1962446211 CVS PHARMACY 0400363 1235114208 COLLEGE HILL HEALTH MART 0400387 1275603359 ALLCARE PHARMACY 0400919 1508972167 MEDIC PHARMACY INC 0413548 1073530465 WAL-MART PHARMACY 0417558 1013956499 SAVON PHARMACY 0422597 1356474449 WALGREENS #10418 0423878 1316213168 ROBERTSON'S NORTH HEIGHTS PHARMACY 0424046 1659629152 CVS PHARMACY #10019 0571782 1629012075 CVS PHARMACY 0619962 1841205192 WALGREENS #9979 1074397 1528162484 CVS PHARMACY 1089526 1598765570 AXIUM HEALTHCARE PHARMACY, INC 1406493 1588779516 RIVERVIEW PHARMACY 1531703 1235144379 WALGREENS #3442 1535371 1619946746 UNIVERSITY RETAIL PHARMACY 1623809 1487977195 KEDO, LLC D/B/A/ VALUMED PHARMACY 1702895 1578645362 GREENHAW PHARMACY INC 1907116 1164448957 HEADRICKS DRUG STORE 1918119 1376561852 WAL-MART PHARMACY 10-0278 1919159 1528085867 WAL-MART PHARMACY 10-0448 1919426 1437176773 WAL-MART PHARMACY 1923920 1154348415 WAL-MART PHARMACY 10-116 1927815 1528051836 NIELSENS PHARMACY 1928552 1932116860 WALGREENS #4304 1930874 1588679757 WALGREENS #7166 1930999 1114932381 WALGREENS #7426 1931472 1265538664 PMO PHARMACY MANAGEMENT SHREVEPORT 1931864 1235145731 WALGREENS #7261 1934113 1669624250 DRYS PHARMACY 2803927 1942368352 THE NEBRASKA MED CENTER CLINIC PHCY 2813687 1184736431 OMNICARE OF NEBRASKA 3200247 1457366353 WALGREENS #4950 3200336 1346455680 RODEN-SMITH PHARMACY 3207241 1982621025 WAL-MART PHARMACY 10-0821 3207811 1073530127 WAL-MART PHARMACY 10-0549 3208041 1174538078 WALGREENS #7930 3208053 1083629984 WALGREENS #2349 3211935 1114255775 WALGREENS
    [Show full text]
  • CVS CAREMARK CORPORATION (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ⌧ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 29, 2007 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-01011 CVS CAREMARK CORPORATION (Exact name of Registrant as specified in its charter) Delaware 050494040 (State or other jurisdiction of (I.R.S. Employer Identification No.) incorporation or organization) One CVS Drive 02895 Woonsocket, Rhode Island (Zip Code) (Address of principal executive offices) (401) 765-1500 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Exchange Act: Common Stock, par value $0.01 per share New York Stock Exchange Title of each class Name of each exchange on which registered Securities registered pursuant to Section 12(g) of the Exchange Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes[X] No[ ] Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes[ ] No[X] Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]